Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.

Louis, Edouard; Belaiche, Jacques

doi:10.1053/bega.2002.0346

Download

Article (Scientific journals)

Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.

Louis, Edouard; Belaiche, Jacques

2003 • In Best Practice and Research. Clinical Gastroenterology, 17 (1), p. 37-46

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/25407

DOI
10.1053/bega.2002.0346

PubMed
12617881

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Postp Aut-Optimizing treatment... Best practice and research clinical Gastroenterology 2003 traité OCR.pdf

Author postprint (179.46 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

6-Mercaptopurine/metabolism/therapeutic use; Azathioprine/metabolism/therapeutic use; Chronic Disease; Humans; Immunosuppressive Agents/metabolism/therapeutic use; Inflammatory Bowel Diseases/drug therapy; Thioguanine/analogs & derivatives/metabolism/therapeutic use

Abstract :

[en] Thioguanine derivatives, azathioprine and 6-mercaptopurine, represent major drugs in the treatment of chronic active inflammatory bowel disease. They are effective in two-thirds of the patients and safe over the long term in patients who can tolerate them (80-90%). Recent progress in understanding the metabolism of these drugs and its implication in clinical practice have brought up new tools and strategies that are proposed to optimize treatment. In particular, the measurement and characterization of key enzymes and metabolites may have clinical impact. Thus, thiopurine methyl transferase genotyping and activity measurement, as well as erythrocytes, 6-thioguanine nucleotides and 6-methyl mercaptopurine levels, may help in some situations of intolerance or inefficacy with these drugs. Indications for starting and stopping treatment with thioguanine derivatives are also discussed.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie - Relations académiques et scientifiques (Médecine)

Belaiche, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Language :

English

Title :

Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.

Publication date :

2003

Journal title :

Best Practice and Research. Clinical Gastroenterology

ISSN :

1521-6918

eISSN :

1532-1916

Publisher :

Bailliere Tindall, London, United Kingdom

Volume :

Issue :

Pages :

37-46

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 October 2009

Statistics

Number of views

65 (2 by ULiège)

Number of downloads

229 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Pearson, D C, May, G R, Fick, G H, Sutherland, L R (1995). Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Annals of Internal Medicine, 123 132-142.
Present, D H, Korelitz, B I, Wisch, N et al. (1980). Treatment of Crohn's with 6-mercaptopurine: a long-term, randomized, double-blind study. New England Journal of Medicine, 302 981-987.
Ewe, K, Press, A G, Singe, C C et al. (1993). Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology, 105 367-372.
Bouhnik, Y, Lémann, M, Mary, J Y et al. (1996). Long-term follow up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet, 347 215-219.
Hawthorne, A B, Logan, R F A, & Hawkey, C J et al. (1992). Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. British Medical Journal, 305 20-22.
Vermeire, S, Louis, E, Carbonez, A et al. (2001). Logistic regression of clinical parameters influencing response to infliximab. Gastroenterology, 120 3149.
Farrell, R J, Alsahli, M, Falchuk, K R et al. (2001). Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy. Gastroenterology, 120 364.
Fraser, A G, Orchard, T R, Jewell, D P (2002). The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 50 485-489.
Rosenberg, J L, Wall, A J, Levin, B et al. (1975). A controlled trial of azathioprine, in the management of chronic ulcerative colitis. Gastroenterology, 69 96-99.
Kirk, A P, Lennard-Jones, J E (1982). Controlled trial of azathioprine in chronic ulcerative colitis. British Medical Journal, 284 1291-1292.
Georges, J, Present, D H, Pou, R et al. (1996). The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. American Journal of Gastroenterology, 91 1711-1714.
Present, D H, Meltzer, S J, Krumholtz, M P et al. (1989). 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Annals of Internal Medicine, 111 641-649.
Connel, W R, Kamm, M A, Ritchie, J K, Lennard-Jones, J E (1993). Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut, 34 1081-1085.
Connel, W R, Kamm, M A, Dickson, M et al. (1994). Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet, 343 1249-1251.
Blondel-Kucharski, F, Chircop, C, Marquis, P et al. (2001). and the GETAID. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. American Journal of Gastroenterology, 96 2915-2920.
Crawford, D J, Maddocks, J, Jones, D N, Szalowski, P (1996). Rational for design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. Journal of Medical Chemistry, 39 63-68.
Weinshilboum, RM, Sladek, S L (1980). Mercaptopurine pharmacogenetics; monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics, 32 651-652.
Szumlanski, C L, Weinshilboum, R M (1995). Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. British Journal of Clinical Pharmacology, 39 456-459.
Dubinsky, M C, Lamothe, S, Yang, H Y et al. (2000). Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 118 705-713.
Dubinsky, M C, Yang, H, Hassard, P V et al. (2002). 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology, 122 904-915.
Vogt, M, Stet, E H, De Abreu, R A et al. (1993). The importance of methylthio-IMP for methylmeraptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochimica et Biophysica Acta, 1181 189-194.
McGovern, D P, Travis, S P, Duley, J (2002). Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology, 122 838-839.
Louis, E, Aboul Nasr El Yafi, F, Belaiche, J (2000). High dose of azathioprine but not 6-mercaptopurine inhibit the production of pro-inflammatory cytokines in inflammatory bowel disease. Gastroenterology, 118 4204.
D'Haens, G, Geboes, K, Ponette, E et al. (1997). Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology, 112 1475-1481.
Markowitz, J, Grancher, K, Kohn, N et al. (2000). A multicenter trial of 6-Mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology, 119 895-902.
Seidman, E G (2000). 6-mercaptopurine in maintaining remission in Crohn's disease: an old friend becomes a new hero. Gastroenterology, 119 1158-1164.
Sandborn, W J, van Os, E C, Zins, B J et al. (1995). An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology, 109 1808-1817.
Mahadevan, U, Tremaine, W J, Johnson, T et al. (2000). Intravenous azathioprine in severe ulcerative colitis: a pilot study. American Journal of Gastroentrology, 95 3463-3468.
Sandborn, W J, Tremaine, W J, Wolf, D C et al. (1999). Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology, 117 527-535.
Colombel, J F, Ferrari, N, Debuysere, H et al. (2000). Genotypic analysis of thiopurine s-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology, 118 1025-1030.
Kaskas, B, Louis, E, Hindorf, U et al. (2002). TPMT-deficient patients with inflammatory bowel disease can be treated safely with azathioprine after dose adjustment. Gut, (in press).
Derijks, L J, De Jong, D J, Gilissen, L P et al. (2001). 6-thioguanine in azathioprine and 6-mercaptopurine intolerant patients with inflammatory bowel disease. British Journal of Clinical Pharmacology, 53 546P-547P.
Dubinsky, M C, Hassard, P V, Seidman, E G et al. (2001). An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflammatory Bowel Disease, 7 181-189.
Barbe, L, Marteau, P, Lémann, M (1998). Dose raising of azathioprine beyond 2.5 mg/kg/d in Crohn's disease who fail to improve with a standard dose. Gastroenterology, 114 G3794.
Cuffari, C, Hunt, S, Bayless, T (2001). Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut, 48 642-646.
Balaiche, J, Desager, J P, Horsmans, Y, Louis, E (2001). Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scandinavian Journal of Gastroenterology, 36 71-76.
Lowry, P W, Franklin, C L, Weaver, A L et al. (2001). Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut, 49 665-670.
Lémann, M, Bouhnik, Y, Kmieciak-le-Corguille, M et al. (1997). Treatment of Crohn's disease with 6-mercaptopurine in patients intolerant to azathioprine. Gastroenterology, 112 A 1025.
Thomsen, J B, Schroder, H, Kristinsson, J et al. (1999). Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Relation to thiopurine metabolism. Cancer, 86 1080-1086.
Lémann, M, Bouhnik, Y, Colombel, J F et al. (2002). Randomized, double-blind, placebo-controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn's disease. Gastroenterology, 122 174.